Resveratrol in cardioprotection: A therapeutic promise of alternative medicine

Molecular Interventions

Volumn 6, Issue 1, 2006, Pages 36-47

  Das, Dipak K ^a   Maulik, Nilanjana ^a,b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIMETHYL 8 CYCLOPENTYLXANTHINE; 1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 (3 CHLOROSTYRYL)CAFFEINE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; AMINOGUANIDINE; ASTRINGININ; DRUG DERIVATIVE; N(G) NITROARGININE METHYL ESTER; PHYTOESTROGEN; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CANCER INHIBITION; CARCINOGENESIS; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; GENE ACTIVATION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; VASODILATATION;

ANTIOXIDANTS; CARDIOTONIC AGENTS; COMPLEMENTARY THERAPIES; HUMANS; ISCHEMIC PRECONDITIONING; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 33644659068     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.6.1.7     Document Type: Review

References (135)

1. Paul, B., Masih, I., Deopujari, J., and Charpentier, C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an Ayurvedic medicine from India. J. Ethnopharmacol. 68, 71-76 (1999). This paper provides evidence that resveratrol was used centuries ago in Ayurvedic medicine.
2. Vastano, B.C., Chen, Y., Zhu, N., Ho, C.T., Zhou, Z., and Rosen, R.T. Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J. Agri. Food Chem. 48, 253-256 (2000).
3. Pezzuto, J.M. Plant-derived anticancer agents. Biochem. Pharmacol. 53, 121-133 (1997).
4. Jang, M., Cai, L., Udenani, G.O. et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220 (1997).
5. Renaud, S. and de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 339, 1523-1526, 1992.
6. Ray, P.S., Maulik, G., Cordis, G.A., Bertelli, A.A., Bertelli, A., and Das, D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury Free Rad. Biol. Med. 27, 160-169 (1999). A pioneering study showing cardioprotective abilities of resveratrol.
7. Hung, L., Chen, J., Huang, S.S., Lee, R., and Su, M. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc. Res. 47, 549-555 (2000).
8. Ignatowicz, E. and Baer-Dubowska W. Resveratrol, a natural chemopreventive agent against degenerative diseases. Pol. J. Pharmacol. 53, 557-569 (2001).
9. Bertelli, A.A., Migliori, M., Panichi, V., Origlia, N., Filippi, C., Das, D.K., and Giovannini, L. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann. N.Y. Acad. Sci. 957, 230-238 (2002).
10. Bhat, K.P., Kosmeder, J.W., II, Pezzuto, J.M. Biological effects of resveratrol. Antiox. Redox Signal. 3, 1041-1064. (2001). An excellent review on the diverse biological activities of resveratrol.
11. Hattori, R., Otani, H., Maulik, N., and Das, D.K. Pharmacological preconditioning with resveratrol: Role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 282, H1988-H1995 (2002). A pioneer study showing the ability of resveratrol to pharmacologically precondition the heart.
12. Das, S., Cordis, G.A., Maulik, N., and Das, D.K. Pharmacological preconditioning with resveratrol: A role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol. 288, H328-H335 (2005). Shows the signaling pathways of the pharmacological preconditioning by resveratrol.
13. Leonard, S., Xia, C., Jiang, B.H., Stinefelt, B., Klandorf, H., Harris, G.K., and Shi, X. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 309, 1017-1026 (2003).
14. Orallo, F., Alvarez, E., Camina, M., Leiro, J.M., Gomez, E., and Fernandez, P. The possible implication of trans-resveratrol in the cardioprotective effects of long-term moderate wine consumption. Mol. Pharmacol. 61, 294-302 (2002). This article shows that the cardioprotective effect of red wine is derived from resveratrol.
15. Martinez, J. and Moreno, J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 59, 865-870, (2000).
16. 3. Free Radic. Biol. Med. 26, 1531-1537 (1999).
17. Lee, S.K., Mbwambo, Z.H., Chung, H., Luyengi, L., Gamez, E.J., Mehta, R.G., Kinghorn, A.D., and Pezzuto, J.M. Evaluation of the antioxidant potential of natural products. Comb. Chem. High Throughput Screen. 1, 35-46 (1998).
18. Kampa, M., Hatzoglou, A., Notas, G., Damianaki, A, Bakogeorgou, E., Gemetzi, C., Kouroumalis, E., Martin, P.M., and Castanas, E. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr. Cancer 37, 223-233 (2000).
19. Manna, S.K., Mukhopadhyay, A., and Aggarwal, B.B. Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. 164, 6509-6519 (200).
20. Ray, P.S., Maulik, G., Cordis, G.A. et al. Myocardial protection by Protykin, a novel extract of trans-resveratrol and emodin. Free Radic. Res. 32, 135-144 (2000).
21. Losa, G.A. Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur. J. Clin. Invest. 33, 818-823 (2003).
22. Olas, B., Wachowicz, B., Bald, E., and Glowacki, R. The protective effects of resveratrol against changes in blood platelet thiols induced by platinum compounds. J. Physiol. Pharmacol. 55, 467-476 (2004).
23. Jang, M. and Pezzuto, J.M. Cancer chemo-preventive activity of resveratrol. Drug Exp. Clin. Res. 25, 65-77 (1999),
24. Yen, G.C., Duh, P.D., and Lin, C.W. Effects of resveratrol and 4-hexylresorcicol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic. Res. 37, 509-514 (2003).
25. Gehm, B.D., McAndrews, J.M., Chien, P.-Y., and Jameson, J.L. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 94, 14138-14143 (1997).
26. Lu, R. and Serrero, G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179, 297-304 (1999).
27. Bowers, J.L., Tyulmenkov, V.V., Jernigan, S.C., and Klinge, C.M. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141, 3657-3667 (2000).
28. Klinge, C.M., Risinger, K.E., Watts, M.B., Beck, V., Eder, R., and Jungbauer, A. Estrogenic activity in white and red wine extracts. J. Agri. Food Chem. 51, 1850-1857 (2003).
29. Henry, L.A. and Witt, DM. Resveratrol: Phytoestrogen effects on reproductive physiology and behavior in female rats. Horm. Behav. 41, 220-228 (2002).
30. Engelman DT, Watanabe M, Maulik N et al. L-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion. Ann. Thoracic Surg. 60, 1275-1281 (1995).
31. Wiseman, H. The therapeutic potential of phytoestrogens. Expert Opin. Investig. Drugs 9, 1829-1840 (2000).
32. Ashby, J., Tinwell, H., Pennie, W., Brooks, A.N., Lefevre, P.A., Beresford, N., and Sumpter, J.P. Partial and weak oestrogenicity of the red wine constituent resveratrol: Consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. J. Appl. Toxicol. 19, 39-45 (1999).
33. Basly, J.P., Marre-Fournier, F., Le Bail, J.C., Habrioux, G., and Chulia, A.J. Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 66, 769-777 (2000).
34. Turner, R.T., Evans, G.L., Zhang, M.. Maran, A., and Sibonga, J.D. Is resveratrol an estrogen agonist in growing rats? Endocrinology 140, 50-54 (1999).
35. Freyberger, A., Hartmann, E., Hildebrand, H., and Krotlinger, F. Differential response of immature rat uterine tissue to ethinylestradiol and the red wine constituent resveratrol. Arch. Toxicol. 11, 709-715 (2001).
36. Mizutani, K., Ikeda, K., Kawai, Y., and Yamori, Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. 46, 78-83 (2000).
37. Levenson, A.S., Gehm, B.D., Pearce, S.T., Horiguchi, J., Simons, L.A., Ward, J.E, III, Jameson, J.L., and Jordan, V.C. Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably tranfected with ERα. Int. J. Cancer 104, 587-596 (2003).
38. Bagchi, D., Das, D.K., Tosaki, A., Bagchi, M., and Kothari, S.C. Benefits of resveratrol in women's health. Drugs Expt. Clin. Res. 27, 233-248 (2001).
39. Bradamante, S., Barenghi, L., Piccinini, F., Bertelli, A.A., De Jonge, R., Beemster, P., De and Jong, J.W. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur. J. Pharmacol. 465, 115-123 (2003). This paper provides evidence for the pharmacologically preconditioning of the heart by resveratrol.
40. Nihei, T., Miura, Y., Yagasaki, K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life Sci. 68, 2845-2852 (2001).
41. Zhao, T., Xi, L., Chelliah, J., Levasseur, M.S., and Kukreja, R.C. Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors. Circulation 102, 902-908 (2001).
42. Carbo, N., Costelli, P., Baccino, M.F., Lopez-Soriano, F.J., and Argiles, J.M. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem. Biophys. Res. Commun. 254, 739-743 (1999).
43. ElAttar, T.M. and Virji, A.S. Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs 10, 187-193 (1999).
44. Caltagirone, S., Rossi, C., Poggi, A., Ranelletti, F.O., Natali, P.G., Brunetti, M., Aiello, F.B., and Piantelli, M. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int. J. Cancer 87, 595-600 (2000).
45. Tessitore, L., Davit, A., Sarotto, I., and Caderni, G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 expression. Carcinogenesis 21, 1619-1622 (2000).
46. Mahady, G.B., Pendland, S.L., and Chadwick, L.R. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am. J. Gastroenterol. 98, 1440-1441 (2003).
47. Mahady, G.B. and Pendland, S.L. Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am. J. Gasteroenterol. 95, 1849 (2000).
48. Hall, S.S. Longevity Research. In vino vitalis? Compounds activate life-extending genes. Science 301, 1165 (2003).
49. Fitzpatrick, D.F., Hirschfield, S.L., and Coffey, R.G. Endothelium-dependent vasorelaxing activity of wine or other grape products. Am. J. Physiol. 265, H774-H748 (1993).
50. Hung, L.M., Chen, J.K., Lee, R.S., Liang, H.C., and Su, M.J. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic. Biol. Med. 30, 877-883 (2001).
51. Imamura, G., Bertelli, A.A., Bertelli, A., Otani, H., Maulik, N., and Das, D.K. Pharmacologic preconditioning with resveratrol: An insight with iNOS knockout mice. Am. J. Physiol. 282, H1996-H2003 (2002). This paper shows that nitric oxide is involved in resveratrol-mediated preconditioning of the heart.
52. Hung, L.M., Su, M.J., and Chen, J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 36, 774-781 (2004). This paper shows that resveratrol can function through both NO-dependent and NO-independent pathways.
53. Das, S., Bertelli, A.A., Bertelli, A., Maulik, N., and Das, D.K. Anti-inflammatory action of resveratrol: A novel mechanism of action. Drugs Exp. Clin. Res. (in press).
54. Pendurthi, U.R., Williams, J.T., and Rao, L.V. Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells: A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine. Arterioscler. Throm. Vasc. Biol. 19, 419-426 (1999).
55. Di Santo, A., Mezzetti, A., Napoleone, E., Di Tommaso, R., Donati, M.B., De Gaetano, G., and Lorenzet, R. Resveratrol and quercetin down-regulate tissue factor expression by human stimulated vascular cells. J. Thromb. Haemost. 1, 1089-1095 (2003).
56. Wang, Z., Huang, Y., Zou, J., Cao, K., Xu, Y., and Wu, J.M. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 9, 77-79 (2002). These results demonstrated that resveratrol can inhibit platelet aggregation.
57. Rotondo, S., Rajtar, G., Manarini, S., Celardo, A., Rotillo, D., de Gaetano, G., Evangelista, V., and Cerletti, C. Effects of trans-resveratrol, a natural polyphenolic compound, on huiman polymorphonuclear leukocyte function. Br. J. Pharmacol. 123, 1691-1699 (1998).
58. Pinto, M.C., Garcia-Barrado, J.A., and Macias, P. Resveratrol is a potent inhibitor of the dioxygenase activity of lipoxygenase. J. Agric. Food Chem. 47, 4842-4846 (1999).
59. Pace-Asciak, C.R., Hahn, S., Diamandis, E.P., Soleas, G., and Goldberg, D.M. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: Implications for protection against coronary heart disease. Clin. Chim. Acta 235, 207-219 (1995).
60. Floreani, M., Napoli, E., Quintieri, L., and Palatini, P. Oral administration of trans-resveratrol to guinera pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atriafrom menadione toxicity. Life Sci. 72, 2741-2750 (2003).
61. Sato, M., Ray, P.S., Maulik, G., Maulik, N., Engelman, R.M., Bertelli, A.A., Bertelli, A., and Das, D.K. Myocardial protection with red wine extract. J. Cardiovasc. Pharmacol. 35, 263-268 (2000). Provides direct experimental evidence for the red wine-mediated cardioprotection.
62. Shigematsu, S., Ishida, S., Hara, M., Takahashi, N., Yoshimatsu, H., Sakata, T., and Korthuis, R.J. Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants. Free Radic. Biol. Med. 34, 810-817 (2003). An excellent paper showing anti-inflammatory action of resveratrol.
63. Sato, M., Maulik, G., Bagchi, D., and Das, D.K. Myocardial protection by protykin, a novel extract of trans-resveratrol and emodin. Free Radic. Res. 32, 135-144 (2000). Provides evidence that a novel formulation of resveratrol with emodin is an excellent cardioprotective agent.
64. El-Mowafy, A.M. and White, R.E. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: Reversal of endothelin-1 stimulatory effects. FEBS Lett. 45, 63-67 (1999).
65. Mitchell, M.B., Meng, X., Ao, L., Brown, J.M., Harken, A.H., and Banerjee, A. Preconditioning of isolated rat heart mediated by protein kinase C. Circ. Res. 76, 73-81 (1995).
66. Flack, J.E., Kimura, Y., Engelman, R.M., and Das, D.K. Preconditioning the heart by repeated stunning improves myocardial salvage. Circulation 84(5 suppl), III369-III374 (1991).
67. Sato, M., Cordis, G.A., Maulik, N., and Das, D.K. SAPKs regulation of ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. 279, H901-H907 (2000).
68. Maulik, N., Wei, Z.J., Engelman, R.M., Lu, D., Rousou, J.A., and Das, DK. Interleukin-1α preconditioning reduces myocardial ischemic reperfusion injury. Circulation 88, 387-394 (1993).
69. Das, D.K., Engelman, R.M., and Kimura, Y. Molecular adaptation of cellular defenses following preconditioning of the heart by repeated ischemia. Cardiovasc. Res. 27, 578-584 (1993).
70. Hattori, R., Maulik, N., Otani, H., Zhu, L., Cordis, G., Engelman, R.M., Siddiqui, M.A.Q., and Das, D.K. Role of Stat 3 in ischemic preconditioning. J. Mol. Cell. Cardiol. (in press)
71. Tanno, M., Tsuchida, A., Nozawa, Y., Matsumoto, T., Hasegawa, T., Miura, T., and Shimamoto, K. Roles of tyrosine kinase and protein kinase C in infarct size limitation by repetitive ischemic preconditioning in the rat. J. Cardiovasc. Pharmacol. 35, 345-352 (2000).
72. Fryer, R.M., Schultz, J.E.J, Hsu AK, and Gross GJ. Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. Am. J. Physiol. 276, H1229-H1235 (1999).
73. Liu, Y., Sato, T., O'Rourke, B., and Marban, E. Mitochondrial ATP-dependent potassium channels-novel effectors of cardioprotection? Circulation 97, 2463-2469 (1998).
74. Berne, R.M. Cardiac nucleotides in hypoxia: Possible role in regulation of coronary blood flow. Am. J. Physiol. 204, 317-322 (1963).
75. Parrat, J.R. and Kane, K.A. KATP channels in ischemic preconditioning. Cardiovasc. Res. 28, 783-787 (1994).
76. Das, D.K., Prasad, M.R., Lu, D., and Jones, R.M. Preconditioning of heart by repeated stunning. Adaptive modification of antioxidant defense system. Cell. Mol. Biol. 38, 739-749 (1992).
77. Das, D.K., Maulik, N., Engelman, R.M., Yoshida, T., and Zu, Y.L. Preconditioning potentiates molecular signaling for myocardial adaptation to ischemia. Ann. N. Y. Acad. Sci. 793, 191-209 (1996).
78. Liu, X., Engelman, R.M., Moraru, I.I., Rousou, J.A., Flack, J.E., Deaton, D.W., Maulik, N., and Das, D.K. Heat Shock. A new approach for myocardial preservation in cardiac surgery. Circulation 86, 358-363 (1992).
79. Maulik, N., Engelman, R.M., Wei, Z., Liu, X., Rousou, J.A., Flack, J,. Deaton, D., and Das, D.K. Drug induced heat shock improves post-ischemic ventriculat recovery after cardiopulmonary bypass. Circulation 92, 381-388 (1995).
80. Maulik, N., Yoshida, T., Zu, Y.L., Banerjee, A., and Das, D.K. Ischemic stress adaptation of heart triggers a tyrosine kinase regulated signaling pathway: A potential role for MAPKAP Kinase 2. Am. J. Physiol. 275, 1857-1864 (1998).
81. Maulik, N., Engelman, R.M., Rousou, J.A., Flack, J.E., Deaton, D., and Das, D.K. Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2. Circulation 100, 369-375 (1999).
82. Maulik, N., Sasaki, H., Addya, S., and Das, D.K. Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett. 485, 7-12 (2000).
83. Guo, Y., Jones, W.K., Xuan, Y.T. et al. The late phase of ischemic preonditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc. Natl. Acad. Sci. USA 96, 11507-11512 (1999).
84. Tosaki, A., Maulik, N., Elliott, G.T., Blasig, I.E., Engelman, R.M., and Das, D.K. Preconditioning of rat heart with monophosphoryl lipid A: A role of nitric oxide. J. Pharmacol. Exp. Ther. 285, 1274-1279 (1998).
85. + channel in mediating the effects of acetylcholine to mimic preconditioning in dogs. Circ. Res. 73, 1193-1201 (1993).
86. Gross, G.J. and Auchampach, J.A. Blockade of ATP-sensitive potassium channel prevents myocardial preconditioning in dogs. Circ. Res. 70, 223-233 (1992).
87. Maulik, N., Watanabe, M., Zu, Y.L, Huang, C.-K., Cordis, G.A., Schley, J.A., and Das, D.K. Ischemic preconditioning triggers the activation of MAP kinases and MAPKAP kinase 2 in rat hearts. FEBS Lett. 396, 233-237 (1996).
88. Ping, P., Zhang, J., Zheng, Y.-T., Li, R.C., Dawn, B., Tang, X.-L., Takano, H., Balafanova, Z., and Bolli, R. Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. Circ. Res. 85, 542-550 (1999).
89. Baines, C.P., Wang, L., Cohen, W.V., and Downey, J.M. Protein tyrosine kinase is downstream of protein kinase C for ischemic preconditioning's anti-infarct effect in the rabbit heart. J. Mol. Cell Cardiol. 30, 383-392 (1998).
90. Gniadecki, R. Nongenomic signaling by vitamin D: A new face of Src. Biochem. Pharmacol. 56, 1273-1277 (1997).
91. Vahlhaus, C., Schulz, R., Post, H., Rose, J., and Heusch, G. Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. J. Mol. Cell. Cardiol. 30, 197-209 (1998).
92. Schlessinger, J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 100, 293-296 (2000).
93. Takeishi, Y., Abe, J., Lee, J.D., Kawakatsu, H., Walsh, R.A., and Berk, B.C. Differential regulation of p90 ribosomal S6 kinase and Big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused guinea pig heart. Circ. Res. 85, 1164-1172 (1999).
94. Abe, J., Takahashi, M., Ishida, M., Lee, J.D., and Berk, B.C. c-Src is required for oxidative stress-mediated activation of Big mitogen-activated protein kinase 1 (BMK1). J. Biol. Chem. 272, 20389-20394 (1997).
95. Akhand, A.A., Pu, M., Senga, T., Kato, M., Suzuki, H., Miyata, T., Hamaguchi, M., and Nakashima, I. Nitric oxide controls Src kinase activity through a sulfhydryl group modification-mediated Tyr-527-independent and Tyr-416-linked mechanism. J. Biol. Chem. 274, 25821-25826 (1999).
96. Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J., and Woodgett, J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369, 156-160 (1994).
97. Hu, Y., Metzler, B., and Xu, Q. Discordant activation of stress-activated protein kinase or c-jun-NH2-terminal protein kinases in tissues of heat stressed mice. J. Biol. Chem. 272, 9113-9119 (1997).
98. Eguchi, S., Numaguchi, K., Iwasaki, H. et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen activated protein kinase activation in vascular smooth muscle cells. J. Biol. Chem. 273, 8890-8896 (1998).
99. Maulik, N., Watanabe, M., Engelman, D., Engelman, R.M., and Das, D.K. Oxidative stress adaptation improives postischemic ventricular recovery. Mol. Cell. Biochem. 144, 67-74 (1995).
100. Abe, J., Bains, C.P., and Berk, B.C. Role of mitogen-activated protein kinases in ischemia and reperfusion injury. Circ. Res. 86, 607-609 (2000).
101. Hattori, R., Otani, H., Uchiyama, T., Imamura, H., Cui, J., Maulik, N., Cordis, G.A., Zhu, L., and Das, D.K. Src tyrosine kinase is the trigger but not the mediator of ischemic preconditioning. Am. J. Physiol. 281, H1066-H1074 (2001).
102. ATP channel. Annu. Rev. Physiol. 62, 79-109 (2000).
103. Cole, W.C., McPherson, C.D., and Sontag, D. ATP-regulated K+ channels protect the myocardium against ischemic/reperfusion damage. Circ. Res. 69, 571-581 (1991).
104. Bedheit, S.S., Restivo, M., Boutjdir, M., Henkin, P., Gooyandeh, K., Assadi, M., Khatib, S., Gough, W.B., and El-Sherif, N. Effects of glyburide on ischemia-induced changes in extracellular potassium and local myocardial activation: A potential new approach to the management of ischemia-induced malignant ventricular arrhythmias. Am. Heart J. 119, 1025-1033 (1990).
105. Baines, C.P., Liu, G.S., Birincioglu, M., Critz, S.D., Cohen, M.V., and Downey, J.M. Ischemic preconditioning depends on interaction between mitochondrial KATP channels and actin cytoskeleton. Am. J. Physiol. 276, H1361-H1368 (1999).
106. Das, D.K., Engelman, R.M., Cherian, K.M. (eds) Myocardial Preservation, Preconditioning, and adaptation. Ann. N.Y. Acad. Sci. 793, 533 (1996).
107. Meerson, F.Z., Pshennikova, M.G., and Malyshev, I.Y. Adaptive defense of the organism. Ann. N. Y. Acad. Sci. 793, 371-385 (1996).
108. Maulik, N., Tosaki, A., Elliott, G.T., Maulik, G., and Das, D.K. Induction of iNOS expression by monophosphoryl lipid A: A pharmacological approach for myocardial adaptation to ischemia. Drugs Exp. Clin. Res. 24, 117-124 (1998).
109. Elliott, G.T. Pharmacologic myocardial preconditioning with monophosphoryl lipid A (MLA) reduces infarct size and stunning in dogs and rabbits Ann. N. Y. Acad. Sci. 793, 386-399 (1996).
110. Fukuda, S., Kaga, S., Zhan, L., Bagchi, D., Das, D.K., Bertelli, A., and Maulik, N. Resveratrol Ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 44, 43-49 (2006). This paper provides the first evidence that resveratrol promotes angiogenesis in the ischemic heart.
111. Sasaki, H., Ray, P.S., Zhu, L., Otani, H., Asahara, T., and Maulik N. Hypoxia/reoxygenation promotes myocardial angiogenesis via an NF kappa B-dependent mechanism in a rat model of chronic myocardial infarction. J. Mol. Cell. Cardiol. 33, 283-294 (2001).
112. Kelly, R.A., Balligand, J.L. and Smith, T.W. Nitric oxisde and cardiac function. Circ. Res. 79, 363-380 (1996).
113. Wildhirt, S.M., Suzuki, H., Horstman, D., Weismuller, S., Dudek, R.R., Akiyama, K. and Reichart, B. Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. Circulation 96, 1616-1623 (1997).
114. Gaballa, M.A., Raya, T.E., Hoover, C.A. and Goldman, S. Effects of endothelial and inducible nitric oxide syntheses inhibition on circulatory function in rats after myocardial infarction. Cardiovasc. Res. 42, 627-635 (1999).
115. Rossig, L., Haendeler, J., Hermann, C., Malchow, P., Urbich, C., Zeiher, A.M., and Dimmeler, S. Nitric oxide down-regulates MKP-3 mRNA levels: Involvement in endothelial cell protection from apoptosis. J. Biol. Chem. 275, 25502-25507 (2000).
116. Dimmeler, S., Haendeler, J., Nehls, M., and Zeiher, A.M. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J. Exp. Med. 185, 601-607 (1997).
117. van der Zee, R., Murohara, T., Luo, Z., Zollmann, F., Passeri, J., Lekutat, C., and Isner, J.M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95, 1030-1037 (1997).
118. Papapetropoulos, A., Garcia-Cardena, G., Madri, J.A., and Sessa, W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139 (1997).
119. Le Cras, T.D., Xue, C., Rengasamy, A., and Johns, R.A. Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. Am. J. Physiol. 270, L164-L170 (1996).
120. Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M., and Heldin, C.H. (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 269, 26988-26995 (1994).
121. Kroll, J. and Waltenberger, J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem. Biophys. Res. Commun. 252, 743-746 (1998).
122. Bussolati, B., Dunk, C., Grohman, M., Kontos, C.D., Mason, J., and Ahmed, A. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am. J. Pathol. 159, 993-1008 (2001).
123. Garthwaite, J. and Boulton, C.L. Nitric oxide signaling in the control nervous system. Annu. Rev. Physiol. 57, 683-706 (1995).
124. Ziche, M. and Morbidelli, L. Nitric oxide and angiogenesis. J. Neurosci. 50, 139-148 (2000).
125. Jozkowicz, A., Cooke, J.P., Guevara, I., Huk, I., Funovics, P., Pachinger, O., Weidinger, F., and Dulak, J. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc. Res. 51, 773-783 (2001).
126. Dimmeler, S., Fleming, I., Fislthaler, B., Hermann, C., Busse, R., and Zeiher, A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605 (1999).
127. Kroll, J. and Waltenberger, J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272, 32521-32527 (1997).
128. Li, J., Brown, L.F., Hibberd, M.G., Grossman, J.D., Morgan, J.P., and Simons, M. VEGF, Flk-1 and Flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. J. Physiol. 270, H1803-H1811 (1996).
129. Das, S., Alagappan, V.K., Bagchi, D., Sharma, H.S., Maulik, N., and Das, D.K. Co-ordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption A potential mechanism for resveratrol preconditioning of the heart. Vasc. Pharmacol. 42, 281-289 (2005). Provides evidence that pharcological preconditiong by resveratrol occurs through angiogenesis.
130. Wallerath, T., Deckert, G., Ternes, T., Anderson, H., Li, H., Witte, K., and Forstermann, U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106, 1652-1658 (2002). Provides evidence that resveratrol induces eNOS activity.
131. Hsieh, T.C., Juan, G., Darzynkiewicz, Z., and Wu, J.M. Resveratrol increases nitric oxide synhase, induces accumulation of p53 and p21, and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing pregression through S to G2. Cancer Res. 59, 2596-2601 (1999).
132. Bertelli, A.A.E., Giovannini, L., Stradi, R., Bertelli, A., and Tillement, J.P. Plasma, urine and tissue levels of trans- and cis- resveratrol (3,4′-trihydroxystilbene) after short-term or prolonged administration of red wine to rats. Int. J. Tissue React. 18, 67-71 (1996).
133. Bertelli, A.A.E., Giovannini, L., Giannessi, D., Migliori, M., Bernini, W., Fregoni, M., and Bertelli, A. Antiplatelet activity of synthetic and natural resveratrol in red wine. Int. J. Tissue React. 17, 1-3 (1995).
134. Ferrero, M.E., Bertelli, A.A.E., Fulgenzi, A., Pellegatta, F., Corsi, M.M., Bonfrate, M., Ferrara, F., De Caterina, R., Giovannini, L., and Bertelli, A. Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am. J. Clin. Nutr. 68, 1208-1214 (1998).
135. Miloso, M., Bertelli, A.A.E., Nicolini, G., and Tredici, G. resveratrol-induced activation of the mitogen-activated protein kinases ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 264, 141-144 (1999).